ABIVAX: Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'

PARIS, FRANCE / ACCESSWIRE / April 28, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the publication of its 2022 Universal Registration Document (Document d'Enregistrement Universel 2022), filed with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), on April 28, 2022.

The Registration Document includes the 2021 Annual Report and the corporate governance report, prepared by the Board of Directors, as well as the conclusions of the statutory auditors.

Copies of the document are available free of charge at the Abivax headquarters on 5, rue de la Baume, 75008 Paris as well as in electronic form via the website of both Abivax (www.abivax.com) and the French Financial Market Authorities (www.amf-france.org). An English translation of the Universal Registration Document will be available on May 13, 2022 at the latest.

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX.

Contacts

Abivax
Communications
Regina Jehle
[e-mail]
[phone]

Investors
LifeSci Advisors
Ligia Vela-Reid
[e-mail]
[phone]

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
[e-mail]
[phone]

Public Relations France
Actifin
Ghislaine Gasparetto
[e-mail]
[phone]

Public Relations France
Primatice
Thomas Roborel de Climens
[e-mail]
[phone]

Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
[e-mail]
[phone]

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Special consideration should be given to the potential hurtles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and ethics committees of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC, clinical data, Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

SOURCE: ABIVAX

View source version on accesswire.com:
https://www.accesswire.com/699318/Abivax-Publishes-Universal-Registration-Document-2022-Document-dEnregistrement-Universel